Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors

Author: Noguchi Atsutaka   Kaneko Toru   Kamigaki Takashi   Fujimoto Katsunada   Ozawa Masanori   Saito Masashi   Ariyoshi Naoko   Goto Shigenori  

Publisher: Ashgate Publishing Ltd

ISSN: 1465-3249

Source: Cytotherapy, Vol.13, Iss.1, 2011-01, pp. : 92-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content